Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Wilson Website

Wyndham Wilson, M.D., Ph.D.

Selected Publications

1)  Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Haematologica. [Epub ahead of print], 2014.
2)  Roschewski M, Staudt LM, Wilson WH.
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 11: 12-23, 2014.
3)  Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian J, Wilson WH, Van Etten RA.
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Leuk. Lymphoma. [Epub ahead of print], 2014.
4)  Roschewski M, Manasanch EE, Wilson WH.
Management of heavy chain diseases: the challenges of biologic heterogeneity.
Oncology. 28: 63-5, 2014.
5)  Roschewski M, Dunleavy K, Wilson WH.
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
6)  Bax HI, Freeman AF, Anderson VL, Vesterhus P, Laerum D, Pittaluga S, Wilson WH, Holland SM.
B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency.
J. Clin. Immunol. 33: 1062-6, 2013.
7)  Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
N. Engl. J. Med. 368: 1408-16, 2013.
8)  Dunleavy K, Wilson WH.
Implications of the shifting pathobiology of AIDS-related lymphoma.
J. Natl. Cancer Inst. 105: 1170-1, 2013.
9)  Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E.
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110: 18250-5, 2013.
10)  Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH.
Low-intensity therapy in adults with Burkitt"s lymphoma.
N. Engl. J. Med. 369: 1915-25, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 5/20/2014.